Cargando…
Fluorescent Advanced Glycation End Products and Their Soluble Receptor: The Birth of New Plasmatic Biomarkers for Risk Stratification of Acute Coronary Syndrome
OBJECTIVE: Advanced glycation end products (AGEs) have pathophysiological implications in cardiovascular diseases. The aim of our study was to evaluate the prognostic value of fluorescent AGEs and its soluble receptor (sRAGE) in the context of acute coronary syndrome (ACS), both in-hospital phase an...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3772878/ https://www.ncbi.nlm.nih.gov/pubmed/24058542 http://dx.doi.org/10.1371/journal.pone.0074302 |
_version_ | 1782284378537197568 |
---|---|
author | Raposeiras-Roubín, Sergio Rodiño-Janeiro, Bruno K. Paradela-Dobarro, Beatriz Grigorian-Shamagian, Lilian García-Acuña, José M. Aguiar-Souto, Pablo Jacquet-Hervet, Michel Reino-Maceiras, María V. González-Juanatey, José R. Álvarez, Ezequiel |
author_facet | Raposeiras-Roubín, Sergio Rodiño-Janeiro, Bruno K. Paradela-Dobarro, Beatriz Grigorian-Shamagian, Lilian García-Acuña, José M. Aguiar-Souto, Pablo Jacquet-Hervet, Michel Reino-Maceiras, María V. González-Juanatey, José R. Álvarez, Ezequiel |
author_sort | Raposeiras-Roubín, Sergio |
collection | PubMed |
description | OBJECTIVE: Advanced glycation end products (AGEs) have pathophysiological implications in cardiovascular diseases. The aim of our study was to evaluate the prognostic value of fluorescent AGEs and its soluble receptor (sRAGE) in the context of acute coronary syndrome (ACS), both in-hospital phase and follow-up period. METHODS: A prospective clinical study was performed in patients with debut’s ACS. The endpoints were the development of cardiac events (cardiac deaths, re-infarction and new-onset heart failure) during in-hospital phase and follow-up period (366 days, inter-quartile range: 273–519 days). 215 consecutive ACS patients admitted to the coronary care unit (62.7±13.0 years, 24.2% female) were included. 47.4% had a diagnosis of ST segment elevation myocardial infarction. AGEs and sRAGE were analysed by fluorescence spectroscopy and competitive ELISA, respectively. Risk scores (GRACE, TIMI, PURSUIT) were calculated retrospectively using prospective data. The complexity of coronary artery disease was evaluated by SYNTAX score. RESULTS: The mean fluorescent AGEs and sRAGE levels were 57.7±45.1 AU and 1045.4±850.0 pg/mL, respectively. 19 patients presented cardiac events during in-hospital phase and 29 during the follow-up. In-hospital cardiac events were significantly associated with higher sRAGE levels (p = 0.001), but not long-term cardiac events (p = 0.365). Regarding fluorescent AGE the opposite happened. After multivariate analysis correcting by gender, left ventricular ejection fraction, glucose levels, haemoglobin, GRACE and SYNTAX scores, sRAGE was significantly associated with in-hospital prognosis, whereas fluorescent AGEs was significantly associated with long-term prognosis. CONCLUSIONS: We conclude that elevated values of sRAGE are associated with worse in-hospital prognosis, whereas high fluorescent AGE levels are associated with more follow-up events. |
format | Online Article Text |
id | pubmed-3772878 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-37728782013-09-20 Fluorescent Advanced Glycation End Products and Their Soluble Receptor: The Birth of New Plasmatic Biomarkers for Risk Stratification of Acute Coronary Syndrome Raposeiras-Roubín, Sergio Rodiño-Janeiro, Bruno K. Paradela-Dobarro, Beatriz Grigorian-Shamagian, Lilian García-Acuña, José M. Aguiar-Souto, Pablo Jacquet-Hervet, Michel Reino-Maceiras, María V. González-Juanatey, José R. Álvarez, Ezequiel PLoS One Research Article OBJECTIVE: Advanced glycation end products (AGEs) have pathophysiological implications in cardiovascular diseases. The aim of our study was to evaluate the prognostic value of fluorescent AGEs and its soluble receptor (sRAGE) in the context of acute coronary syndrome (ACS), both in-hospital phase and follow-up period. METHODS: A prospective clinical study was performed in patients with debut’s ACS. The endpoints were the development of cardiac events (cardiac deaths, re-infarction and new-onset heart failure) during in-hospital phase and follow-up period (366 days, inter-quartile range: 273–519 days). 215 consecutive ACS patients admitted to the coronary care unit (62.7±13.0 years, 24.2% female) were included. 47.4% had a diagnosis of ST segment elevation myocardial infarction. AGEs and sRAGE were analysed by fluorescence spectroscopy and competitive ELISA, respectively. Risk scores (GRACE, TIMI, PURSUIT) were calculated retrospectively using prospective data. The complexity of coronary artery disease was evaluated by SYNTAX score. RESULTS: The mean fluorescent AGEs and sRAGE levels were 57.7±45.1 AU and 1045.4±850.0 pg/mL, respectively. 19 patients presented cardiac events during in-hospital phase and 29 during the follow-up. In-hospital cardiac events were significantly associated with higher sRAGE levels (p = 0.001), but not long-term cardiac events (p = 0.365). Regarding fluorescent AGE the opposite happened. After multivariate analysis correcting by gender, left ventricular ejection fraction, glucose levels, haemoglobin, GRACE and SYNTAX scores, sRAGE was significantly associated with in-hospital prognosis, whereas fluorescent AGEs was significantly associated with long-term prognosis. CONCLUSIONS: We conclude that elevated values of sRAGE are associated with worse in-hospital prognosis, whereas high fluorescent AGE levels are associated with more follow-up events. Public Library of Science 2013-09-13 /pmc/articles/PMC3772878/ /pubmed/24058542 http://dx.doi.org/10.1371/journal.pone.0074302 Text en © 2013 Raposeiras-Roubín et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Raposeiras-Roubín, Sergio Rodiño-Janeiro, Bruno K. Paradela-Dobarro, Beatriz Grigorian-Shamagian, Lilian García-Acuña, José M. Aguiar-Souto, Pablo Jacquet-Hervet, Michel Reino-Maceiras, María V. González-Juanatey, José R. Álvarez, Ezequiel Fluorescent Advanced Glycation End Products and Their Soluble Receptor: The Birth of New Plasmatic Biomarkers for Risk Stratification of Acute Coronary Syndrome |
title | Fluorescent Advanced Glycation End Products and Their Soluble Receptor: The Birth of New Plasmatic Biomarkers for Risk Stratification of Acute Coronary Syndrome |
title_full | Fluorescent Advanced Glycation End Products and Their Soluble Receptor: The Birth of New Plasmatic Biomarkers for Risk Stratification of Acute Coronary Syndrome |
title_fullStr | Fluorescent Advanced Glycation End Products and Their Soluble Receptor: The Birth of New Plasmatic Biomarkers for Risk Stratification of Acute Coronary Syndrome |
title_full_unstemmed | Fluorescent Advanced Glycation End Products and Their Soluble Receptor: The Birth of New Plasmatic Biomarkers for Risk Stratification of Acute Coronary Syndrome |
title_short | Fluorescent Advanced Glycation End Products and Their Soluble Receptor: The Birth of New Plasmatic Biomarkers for Risk Stratification of Acute Coronary Syndrome |
title_sort | fluorescent advanced glycation end products and their soluble receptor: the birth of new plasmatic biomarkers for risk stratification of acute coronary syndrome |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3772878/ https://www.ncbi.nlm.nih.gov/pubmed/24058542 http://dx.doi.org/10.1371/journal.pone.0074302 |
work_keys_str_mv | AT raposeirasroubinsergio fluorescentadvancedglycationendproductsandtheirsolublereceptorthebirthofnewplasmaticbiomarkersforriskstratificationofacutecoronarysyndrome AT rodinojaneirobrunok fluorescentadvancedglycationendproductsandtheirsolublereceptorthebirthofnewplasmaticbiomarkersforriskstratificationofacutecoronarysyndrome AT paradeladobarrobeatriz fluorescentadvancedglycationendproductsandtheirsolublereceptorthebirthofnewplasmaticbiomarkersforriskstratificationofacutecoronarysyndrome AT grigorianshamagianlilian fluorescentadvancedglycationendproductsandtheirsolublereceptorthebirthofnewplasmaticbiomarkersforriskstratificationofacutecoronarysyndrome AT garciaacunajosem fluorescentadvancedglycationendproductsandtheirsolublereceptorthebirthofnewplasmaticbiomarkersforriskstratificationofacutecoronarysyndrome AT aguiarsoutopablo fluorescentadvancedglycationendproductsandtheirsolublereceptorthebirthofnewplasmaticbiomarkersforriskstratificationofacutecoronarysyndrome AT jacquethervetmichel fluorescentadvancedglycationendproductsandtheirsolublereceptorthebirthofnewplasmaticbiomarkersforriskstratificationofacutecoronarysyndrome AT reinomaceirasmariav fluorescentadvancedglycationendproductsandtheirsolublereceptorthebirthofnewplasmaticbiomarkersforriskstratificationofacutecoronarysyndrome AT gonzalezjuanateyjoser fluorescentadvancedglycationendproductsandtheirsolublereceptorthebirthofnewplasmaticbiomarkersforriskstratificationofacutecoronarysyndrome AT alvarezezequiel fluorescentadvancedglycationendproductsandtheirsolublereceptorthebirthofnewplasmaticbiomarkersforriskstratificationofacutecoronarysyndrome |